Kathleen Kuo Ho

Dr. Kathleen Kuo Ho

Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in Molecules
Verified
Journal Article
Open access
PDF file
ASAlex Straiker
Alex Straiker
SWSierra Wilson
Sierra Wilson
WCWesley Corey
Wesley Corey
MDMichaela Dvorakova
Michaela Dvorakova
TBTaryn Bosquez
Taryn Bosquez
KMKen Mackie
Ken Mackie
Cannabis contains more than 100 phytocannabinoids. Most of these remain poorly characterized, particularly in neurons. We tested a panel of five phytocannabinoids—cannabichromene (CBC), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), and Δ9-tetrahydrocannabivarin (THCV) in two neuronal models, autaptic hippocampal neurons and dorsal root ganglion (DRG) neurons. Autaptic neurons expressed a form of CB1-dependent retrograde plasticity while DRGs expressed a variety of transient receptor potential (TRP) channels. CBC, CBDA, and CBDVA had little or no effect on neuronal cannabinoid signaling. CBDV and THCV differentially inhibited cannabinoid signaling. THCV inhibited CB1 receptors presynaptically while CBDV acted post-synaptically, perhaps by inhibiting 2-AG production. None of the compounds elicited a consistent DRG response. In summary, we find that two of five ‘minor’ phytocannabinoids tested antagonized CB1-based signaling in a neuronal model, but with very different mechanisms. Our findings highlight the diversity of potential actions of phytocannabinoids and the importance of fully evaluating these compounds in neuronal models.

27 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Kathleen Kuo HoKathleen Kuo Ho
Kathleen Kuo Ho
NBNicole Elizabeth Bodi
Nicole Elizabeth Bodi
TSTasneem Putliwala Sharma
Tasneem Putliwala Sharma
Glaucoma is a group of optic neuropathies and the world’s leading cause of irreversible blindness. Normal-tension glaucoma (NTG) is a subtype of glaucoma that is characterized by a typical pattern of peripheral retinal loss, in which the patient’s intraocular pressure (IOP) is considered within the normal range (<21 mmHg). Currently, the only targetable risk factor for glaucoma is lowering IOP, and patients with NTG continue to experience visual field loss after IOP-lowering treatments. This demonstrates the need for a better understanding of the pathogenesis of NTG and underlying mechanisms leading to neurodegeneration. Recent studies have found significant connections between NTG and cerebral manifestations, suggesting NTG as a neurodegenerative disease beyond the eye. Gaining a better understanding of NTG can potentially provide new Alzheimer’s Disease diagnostics capabilities. This review identifies the epidemiology, current biomarkers, altered fluid dynamics, and cerebral and ocular manifestations to examine connections and discrepancies between the mechanisms of NTG and Alzheimer’s Disease.

31 December 2022 in Proceedings of IMPRS
Verified
Journal Article
Open access
PDF file
Kathleen Kuo HoKathleen Kuo Ho
Kathleen Kuo Ho
SHShahna Shahul Hameed
Shahna Shahul Hameed
TSTasneem Putliwala Sharma
Tasneem Putliwala Sharma
Purpose: Glaucoma is a group of optic neuropathies characterized by retinal ganglion cell (RGC) death and visual field loss. A degenerative mechanism associated with RGC death is disrupted delivery of neurotropic factors due to glaucomatous axonal damage. This transport is critical for protection of long-term neuronal function. Thus, we investigate a potential therapeutic target, human Neuritin 1 (NRN1), which has demonstrated neuroprotective effects in rodent axonal injury models. Further, the advent of induced pluripotent stem cell (iPSC) technology allows iPSC-RGCs to be generated in-vitro from commercial iPSCs and reprogrammed corneal fibroblasts. We hypothesize delivery of NRN1 and transplantation of iPSC-RGCs will sustain survival of RGCs and ultimately slow progression of glaucoma-induced neuronal death in our ocular translaminar autonomous system (TAS) perfusion model system. This will allow us to analyze a potential therapeutic approach for both early-stage glaucoma (NRN1 therapy) to protect dying RGCs, and late-stage (iPSC-RGCs), when most RGCs are lost. Methods: Human donor eyes were obtained from eye banks according to Declaration of Helsinki. The iPSC-RGCs transfected with AAV2-GFP were seeded into human posterior cups with NRN1 and cultured in TAS model under pressurized conditions for 2 days. Survival of iPSC-RGCs, gliotic and fibrotic pathways were measured through expression by qRT-PCR and immunohistochemistry. Retinal function post-treatment was measured through electroretinogram analysis. Results: We successfully maintained the human posterior eye cups in translaminar differentials for 2 days. In contrast to controls, we observed increased RGC survival and retinal function after combination therapy of NRN1 and iPSC-RGC. Additionally, we found differential gene expression of apoptosis, inflammation, and gliotic markers. Conclusion: Our study identified that NRN1 in conjunction with iPSC-RGC transplantation treatment promotes RGC survival under glaucomatous conditions. This suggests that NRN1 and iPSC-RGCs could be utilized as a potential combination therapy to save retinal neurons and prevent neurodegeneration in glaucoma patients.

24 July 2025 in The Journal of Medicine Access
Verified
Journal Article
Open access
PWPatrick Wurster
Patrick Wurster
MTMargaret Tharp
Margaret Tharp
Kathleen Kuo HoKathleen Kuo Ho
Kathleen Kuo Ho
JEJennifer Eikenberry
Jennifer Eikenberry
Background: Understanding the factors associated with patient no-shows is essential for healthcare providers to develop strategies to optimize patient care, as these can delay care and increase cost. This retrospective study aimed to identify factors associated with higher likelihood of patients missing their scheduled cataract surgery appointments at a county hospital. Methods: A retrospective chart review was performed using data collected from the surgery schedule and electronic medical record on patients aged 18–100 years scheduled for cataract surgery at Eskenazi Hospital between January 1, 2022, and December 31, 2022. Logistic regression was used to compare factors of age, race, ethnicity, primary spoken and written language, insurance status, best-corrected visual acuity and number of admissions to the emergency department of the same hospital in the preceding year to attendance of cataract surgery on scheduled date. Results: This study found that in the studied population (n = 242), being incarcerated was a statistically significant predictor of missing the scheduled cataract surgery appointment (OR 6.14, 95% CI 1.14–33.16, p = 0.035). In addition, having at least one emergency department visit in the prior year (OR 6.50, CI 1.83–23.1, p = 0.004) was found to be significant, with a greater difference in patients who had at least three emergency department visits in the prior year (OR 13.2, CI 3.21–52.6, p < 0.001). Other studied factors were not found to be statistically significant predictors of missing the surgery appointment, although having best-corrected vision of count fingers or worse neared statistical significance of predicting missing cataract surgery appointment. These findings may potentially direct targeted intervention strategies to improve access to cataract care.